stockportfolio.pro
MBX Biosciences, Inc. (MBX)
Healthcare · Biotechnology · NasdaqGS
MBX Biosciences, Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — |
| Net income | $-26.14M | $-32.56M | $-61.92M | $-86.97M |
| Net margin | — | — | — | — |
Source: MBX Biosciences, Inc. SEC filings (10-K).
Explore 4 years of MBX Biosciences, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MBX in your portfolio →
MBX Biosciences, Inc. financial history by metric
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Biosciences, Inc. — frequently asked questions
What is MBX Biosciences, Inc.'s revenue?
MBX Biosciences, Inc. (MBX) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is MBX Biosciences, Inc. profitable?
No — MBX reported a net loss of $-86.97M in fiscal 2025.
What is MBX's P/E ratio?
MBX Biosciences, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does MBX Biosciences, Inc. have?
As of fiscal year 2025, MBX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is MBX Biosciences, Inc.'s market cap?
MBX Biosciences, Inc. (MBX) has a market capitalization of about $1.57B, based on the latest data in our nightly-refreshed cache.
When does MBX Biosciences, Inc.'s fiscal year end?
MBX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from MBX Biosciences, Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.